Sign in
4

Changes in Ownership

Tarsus Pharmaceuticals, Inc. Filed Acc 0001519692-23-000006

Chief Financial Officer sold 5,313 shares at an average $13.44 ($71,404)

  • Chief Financial Officer acquired 4,462 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Greenstein Leonard M. · Chief Financial Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2023-03-15 Exercise or conversion : show line 1 in the form +4,462 38,751 D
2023-03-16 Sale : show line 2 in the form −313 $13.43 $4,204 38,438 D
2023-03-16 Sale : show line 3 in the form −5,000 $13.44 $67,200 33,438 D
Open-market sales · 5,313 sh · avg $13.44 · $71,404

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-03-15 Exercise or conversion : show line 4 in the form Restricted Stock Units −4,462 13,388 D
Loading xslF345X03/wf-form4_167909066577368.xml…